All News
Filter News
Found 808,462 articles
-
Laurent Pharmaceuticals Receives Health Canada’s Approval to Initiate Phase 2/3 Clinical Trial in Long COVID
8/29/2023
Laurent Pharmaceuticals Inc., a Montreal-based biopharmaceutical company, today announced that it has obtained the approval from Health Canada to initiate ESSOR, an adaptive Phase 2/3 randomized placebo-controlled trial testing its oral drug candidate LAU-7b as a potential treatment for Long COVID.
-
Olink to participate in September 2023 investor events
8/29/2023
Olink Holding AB, announced that Company management will participate in the following investor events.
-
XORTX Submits Orphan Drug Designation Application to the European Medicines Agency (EMA) to Treat Progressive Kidney Disease
8/29/2023
XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that it has submitted an Orphan Drug Designation application for XORLO™ to the European Medicines Agency (the “EMA”).
-
MBX Biosciences to Participate in Morgan Stanley Global Healthcare Conference
8/29/2023
MBX Biosciences, Inc. announced that Kent Hawryluk, President and Chief Executive Officer, and Richard Bartram, Chief Financial Officer, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on Tuesday, September 12th, 2023, at 11:30 a.m. Eastern Time and will host 1-on-1 investor meetings.
-
Arbor Biotechnologies Appoints Ajim Tamboli as Chief Financial Officer
8/29/2023
Arbor Biotechnologies®, a biotechnology company discovering and developing the next generation of genetic medicines, announced the appointment of Ajim Tamboli, CFA, as its Chief Financial Officer.
-
Omega Therapeutics Announces Updates to its Board of Directors - August 29, 2023
8/29/2023
Omega Therapeutics, Inc. announced that Chris Schade has been appointed as Chairman of the Board, succeeding Noubar Afeyan, Ph.D. In addition, Michelle C. Werner will join Omega’s Board to support the Company’s growth.
-
Apellis Announces Corporate Restructuring to Drive Growth of SYFOVRE® (pegcetacoplan injection) and EMPAVELI® (pegcetacoplan), Positioning Company for Long-Term Success
8/29/2023
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) (the “Company”), a global biopharmaceutical company and leader in complement, today announced a corporate restructuring to drive growth of SYFOVRE® (pegcetacoplan injection) and EMPAVELI® (pegcetacoplan), positioning Apellis for long-term success.
-
Eagle Pharmaceuticals Announces Positive Type C Meeting with FDA for EA-114, an Estrogen Receptor Antagonist Used in the Treatment of Metastatic Breast Cancer in Post-Menopausal Women
8/29/2023
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced a positive Type C meeting with the U.S. Food and Drug Administration (“FDA”). Eagle and the FDA agreed on a path forward to advance the clinical development of EA-114, an estrogen receptor antagonist used in the treatment of breast cancer in post-menopausal women.
-
Entrada Therapeutics to Present at Upcoming September 2023 Investor Conferences
8/29/2023
Entrada Therapeutics, Inc., a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle -therapeutics as a new class of medicines, announced the Company will participate in two investor conferences in September.
-
Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN I Trial of LYR-210 for the Treatment of Chronic RhinosinusitisTopline Results Expected 1H 2024
8/29/2023
Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting anti-inflammatory therapies for the localized treatment of chronic rhinosinusitis (CRS), today announced that the pivotal Phase 3 ENLIGHTEN I clinical trial of LYR-210 in adult patients with CRS who have not had prior ethmoid sinus surgery, is fully enrolled.
-
NRx Pharmaceuticals Announces Definitive Purchase Agreement for Preferred Shares at $0.40 per share
8/29/2023
NRx Pharmaceuticals, Inc. announced that it entered into a definitive purchase agreement subject to standard closing conditions with accredited investors to purchase 3,000,000 shares of preferred stock at $0.40 per share, which will convert, after six months into 3,000,000 common shares and 3,000,000 warrants to purchase common stock at a purchase price of $0.40 per share; the term on these warrants is five years.
-
Novocure Announces The Lancet Oncology Publishes Primary Data from Phase 3 LUNAR Clinical Trial in Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
8/29/2023
Novocure (NASDAQ: NVCR) announced today that data from the randomized phase 3 LUNAR clinical trial evaluating the use of Tumor Treating Fields (TTFields) therapy together with standard systemic therapies for the treatment of metastatic non-small cell lung cancer (NSCLC) following progression on or after platinum-based therapy have been published in The Lancet Oncology.
-
Reneo Pharmaceuticals to Participate in Upcoming September 2023 Investor Conferences
8/29/2023
Reneo Pharmaceuticals, Inc. announced that the company’s management team will participate at the upcoming healthcare investor conferences.
-
Vetter earns Frost & Sullivan’s Customer Value Award for the third time
8/29/2023
Identified as best-in-class CDMO in global biopharmaceutical aseptic fill-and-finish services
-
RS BioTherapeutics and National Institutes of Health Execute Research Collaboration Agreement to Evaluate Prevention and Treatment of Idiopathic Pulmonary Fibrosis
8/29/2023
RS BioTherapeutics has entered into a Research Collaboration Agreement with the National Institute on Alcohol Abuse and Alcoholism (NIAAA), an institute within the National Institutes of Health (NIH), to assess the anti-inflammatory and anti-fibrotic potential of RS BioTherapeutics’ lead compound, RSBT-001, in a preclinical pulmonary fibrosis model.
-
Foresee Pharmaceuticals Announces FDA Orange Book Listing of New U.S. Patent for CAMCEVI®, Extending Patent Protection to 2039
8/29/2023
Foresee Pharmaceuticals (TPEx: 6576), ("Foresee") today announces that a new U.S. patent which covers CAMCEVI® (leuprolide mesylate) and its labeled indication is now listed in the U.S. Food and Drug Administration (FDA) publication Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as "the Orange Book".
-
FibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambulatory Duchenne Muscular Dystrophy
8/29/2023
FibroGen, Inc. (NASDAQ: FGEN) today announced topline data from the Phase 3 LELANTOS-2 trial of pamrevlumab for the treatment of ambulatory patients with Duchenne muscular dystrophy (DMD) on background systemic corticosteroids.
-
Nufactor® Announces its Partnership with Verrica Pharmaceuticals to be the Exclusive Specialty Pharmacy to Provide YCANTH™, the First FDA Approved Treatment for Molluscum Contagiosum
8/29/2023
Nufactor, Inc., a specialty pharmacy and subsidiary of FFF Enterprises Inc., announced that it has partnered with Verrica Pharmaceuticals to be the exclusive specialty pharmacy to dispense YCANTH™, the first FDA approved treatment of molluscum contagiosum in adult and pediatric patients 2 years of age and older.
-
JanOne Earns US Patent for the Use of its Novel Formulation of Low-Dose Naltrexone, Jan123, to Treat Chronic Pain
8/29/2023
JanOne (Nasdaq: JAN), the visionary biotech company dedicated to discovering non-addictive treatments for pain, as well as causes of pain, has earned a US patent for its innovative formulation of low-dose naltrexone, Jan123, for treating pain.
-
CCM Biosciences Launches from Stealth to Advance Portfolio of Proprietary, First-in-Class Therapies and Companion Diagnostic Tests Across Multiple Therapeutic Areas
8/29/2023
Diversified biotechnology company CCM Biosciences launched from stealth with more than ten drug programs, many of which originated from CCM Biosciences' proprietary drug discovery platforms.